U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07551167) titled 'A Phase I Study of HRS-5765 in Healthy Participants' on April 20.
Brief Summary: The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of HRS-5765 in healthy participants.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Heart Failure
Intervention:
DRUG: HRS-5765 Tablet
HRS-5765 tablet, specified dose on specified day.
DRUG: HRS-5765 Tablet Placebo
HRS-5765 tablet placebo, specified dose on specified day.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Chengdu Suncadia Medicine Co., Ltd.
Disclaimer: Curated by HT Syndication....